Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
Crossref DOI link: https://doi.org/10.1186/s12981-016-0101-3
Published Online: 2016-04-02
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
,
de Castro, Nathalie
Braun, Joséphine
Charreau, Isabelle
Lafeuillade, Alain
Viard, Jean-Paul
Allavena, Clotilde
Aboulker, Jean-Pierre
Molina, Jean-Michel
Funding for this research was provided by:
Agence Nationale de Recherches sur le Sida et les Hepatites Virales
